Methamphetamine Antikörper (Cy5)

Produktnummer ABIN677292

This anti-Methamphetamine antibody (ABIN677292) is a Rabbit Polyclonal antibody detecting Methamphetamine in WB, IF (cc), IF (p). Suitable for .

Kurzübersicht für Methamphetamine Antikörper (Cy5) (ABIN677292)

Target: Methamphetamine (M-Amp)

Reaktivität: Bitte anfragen

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Methamphetamine Antikörper ist konjugiert mit Cy5

Applikation: Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Produktdetails anti-Methamphetamine Antikörper (Cy5)

Kreuzreaktivität (Details): Methamphetamine

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated to Methamphetamine

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu Methamphetamine

Target: Methamphetamine (M-Amp)

Andere Bezeichnung: Methamphetamine

Substanzklasse: Chemical

Hintergrund:

Synonyms: d-Desoxyephedrine hydrochloride, d-N, -Dimethylphenethylamine hydrochloride, Methylamphetamine hydrochloride.

Background: Methamphetamine (METH) is closely related chemically to amphetamine (AMPH). METH is a potent central nervous system stimulant with additional peripheral sympathomimetic effects. METH and AMPH have been used clinically in the treatment of obesity, minimal brain dysfunction, narcolepsy, depression and to counter fatigue. They are also subjected to widespread abuse. METH is an indirect agonists. It causes the release of newly synthesized norepinephrine and dopamine and it blocks the re uptake of these transmitters from the synapse. This can lead to an increase in the concentration of catecholamines in the synapse as well as an overall increase in catecholaminergic activity in the brain. The mechanism of METH induced neurotoxicity for all monoaminergic cell types may lie primarily with the dopaminergic system in the striatum. It may also lie with the interaction between METH induced release of dopamine and its ability to inhibit monoamine oxidase.